US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Blade Therapeutics, Inc.
Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022
September 04, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
August 01, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Tickers
BIOT
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 18, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Tickers
BIOT
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 16, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Tickers
BIOT
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
April 04, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Tickers
BIOT
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
March 24, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Tickers
BIOT
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
January 12, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Tickers
BIOT
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
November 30, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development
November 18, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
October 18, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis
October 14, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Mourns the Passing of General Counsel and Secretary Alan C. Mendelson
October 11, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease
October 07, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)
September 20, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)
August 25, 2021
From
Blade Therapeutics, Inc.
Via
Business Wire
